Knockdown of Sox2 Inhibits OS Cells Invasion and Migration via Modulating Wnt/β-Catenin Signaling Pathway

Original Article

Abstract

Osteosarcoma (OS) was a prevalent malignant bone tumor which threatens people’s health worldwide. Wnt/β catenin signaling pathway had been proved significant in various cancers, indicating its possible function in OS as well. Sox2, a crucial member among SOX family could regulate cells biologically. How Sox2 modulated Wnt/β catenin signaling pathway in OS remained to be discussed. The study aimed to investigate the effects of Sox2 on the invasion and migration of OS cells and the related molecular mechanisms. Twenty-four human OS and adjacent tissue samples were involved in this study. Human OS cell lines MG63 and HOS were selected for further investigation. The liposome carrier si-Sox2 which could interfere with the expression of Sox2 gene was built to transfect MG63 and HOS cells). QRT-PCR assay and western blot were utilized to analyze the expression of mRNA and proteins of Sox2. Transwell assay and wound healing assay were conducted to test the invasion and migration level of cells. The expression of GSK3, β-catenin, cyclin D1 and c-myc proteins were detected by western blot assay after transfection with si-Sox2. Compared with normal tissues and cells, the expression of Sox2 in OS tissues and cells was significantly higher. The mRNA and protein levels of Sox2 significantly decreased after transfection with si-Sox2. The invasion and migration of OS cells were down-regulated significantly through the inhibition of Sox2 by inactivating Wnt/β-catenin signaling pathway related proteins. Knockdown of Sox2 could inhibit invasion and migration of OS cells via modulating Wnt/β-catenin signaling pathway.

Keywords

Osteosarcoma Sox2 Wnt/β-catenin 

Notes

Compliance with Ethical Standards

Conflict of Interest

No conflict of interest exits in the submission of this manuscript and this manuscript has been approved by all authors for publication.

References

  1. 1.
    Niu G, Li B, Sun L, An C (2015) MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-beta2. PLoS One 10(3):e0119225.  https://doi.org/10.1371/journal.pone.0119225 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108.  https://doi.org/10.3322/caac.21262 CrossRefPubMedGoogle Scholar
  3. 3.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, XQ Y, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132.  https://doi.org/10.3322/caac.21338 CrossRefPubMedGoogle Scholar
  4. 4.
    Isakoff MS, Bielack SS, Meltzer P, Gorlick R (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol Off J Am Soc Clin Oncol 33(27):3029–3035.  https://doi.org/10.1200/JCO.2014.59.4895 CrossRefGoogle Scholar
  5. 5.
    Zhang RX, Li Y, Tian DD, Liu Y, Nian W, Zou X, Chen QZ, Zhou LY, Deng ZL, He BC (2016) Ursolic acid inhibits proliferation and induces apoptosis by inactivating Wnt/beta-catenin signaling in human osteosarcoma cells. Int J Oncol 49(5):1973–1982.  https://doi.org/10.3892/ijo.2016.3701 CrossRefPubMedGoogle Scholar
  6. 6.
    Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S, Bakhshi S (2015) Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: a single-center experience of 237 patients. J Surg Oncol 112(6):662–668.  https://doi.org/10.1002/jso.24045 CrossRefPubMedGoogle Scholar
  7. 7.
    Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A, Basilico C (2012) Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 31(18):2270–2282.  https://doi.org/10.1038/onc.2011.405 CrossRefPubMedGoogle Scholar
  8. 8.
    Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol Off J Am Soc Clin Oncol 30(20):2545–2551.  https://doi.org/10.1200/JCO.2011.37.4546 CrossRefGoogle Scholar
  9. 9.
    Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA, Children's Oncology G (2009) Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 115(22):5339–5348.  https://doi.org/10.1002/cncr.24566 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Endicott AA, Morimoto LM, Kline CN, Wiemels JL, Metayer C, Walsh KM (2017) Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents. Pediatr Blood Cancer 64(6).  https://doi.org/10.1002/pbc.26349
  11. 11.
    Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E, Menendez P, Garcia-Castro J, Rodriguez R (2015) Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci 72(16):3097–3113.  https://doi.org/10.1007/s00018-015-1918-y CrossRefPubMedGoogle Scholar
  12. 12.
    Zhu XB, Zhang ZC, Han GS, Han JZ, Qiu DP (2017) Overexpression of miR214 promotes the progression of human osteosarcoma by regulating the Wnt/betacatenin signaling pathway. Mol Med Rep 15(4):1884–1892.  https://doi.org/10.3892/mmr.2017.6203 CrossRefPubMedGoogle Scholar
  13. 13.
    Zhan P, Zhang B, Xi GM, Wu Y, Liu HB, Liu YF, WJ X, Zhu QQ, Cai F, Zhou ZJ, Miu YY, Wang XX, Jin JJ, Li Q, Qian LP, Lv TF, Song Y (2017) PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/beta-catenin signaling pathway. Mol Cancer 16(1):108.  https://doi.org/10.1186/s12943-017-0682-z CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Peng L, Liu Z, Xiao J, Tu Y, Wan Z, Xiong H, Li Y, Xiao W (2017) MicroRNA-148a suppresses epithelial-mesenchymal transition and invasion of pancreatic cancer cells by targeting Wnt10b and inhibiting the Wnt/beta-catenin signaling pathway. Oncol Rep 38(1):301–308.  https://doi.org/10.3892/or.2017.5705 CrossRefPubMedGoogle Scholar
  15. 15.
    Zhu B, Cheng D, Li S, Zhou S, Yang Q (2016) High expression of XRCC6 promotes human osteosarcoma cell proliferation through the beta-catenin/Wnt signaling pathway and is associated with poor prognosis. Int J Mol Sci 17(7).  https://doi.org/10.3390/ijms17071188
  16. 16.
    Lin CH, Ji T, Chen CF, Hoang BH (2014) Wnt signaling in osteosarcoma. Adv Exp Med Biol 804:33–45.  https://doi.org/10.1007/978-3-319-04843-7_2 CrossRefPubMedGoogle Scholar
  17. 17.
    Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM (2010) Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 220(1):24–33.  https://doi.org/10.1002/path.2628 CrossRefPubMedGoogle Scholar
  18. 18.
    Jin Z, Han YX, Han XR (2013) Degraded iota-carrageenan can induce apoptosis in human osteosarcoma cells via the Wnt/beta-catenin signaling pathway. Nutr Cancer 65(1):126–131.  https://doi.org/10.1080/01635581.2013.741753 CrossRefPubMedGoogle Scholar
  19. 19.
    Yang C, Hou C, Zhang H, Wang D, Ma Y, Zhang Y, Xu X, Bi Z, Geng S (2013) miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci 15(1):423–437.  https://doi.org/10.3390/ijms15010423 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Moradi A, Ghasemi F, Anvari K, Hassanian SM, Simab SA, Ebrahimi S, Hesari A, Forghanifard MM, Boroushaki MT, ShahidSales S, Avan A (2017) The cross-regulation between SOX15 and Wnt signaling pathway. J Cell Physiol 232(12):3221–3225.  https://doi.org/10.1002/jcp.25802 CrossRefPubMedGoogle Scholar
  21. 21.
    Hussenet T, du Manoir S (2010) SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle 9(8):1480–1486.  https://doi.org/10.4161/cc.9.8.11203 CrossRefPubMedGoogle Scholar
  22. 22.
    Ten Kate FJC, van Olphen SH, Bruno MJ, Wijnhoven BPL, van Lanschot JJB, Looijenga LHJ, Fitzgerald RC, Biermann K (2017) Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. Br J Surg 104(10):1327–1337.  https://doi.org/10.1002/bjs.10553 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    He J, Shi J, Zhang K, Xue J, Li J, Yang J, Chen J, Wei J, Ren H, Liu X (2017) Sox2 inhibits Wnt-beta-catenin signaling and metastatic potency of cisplatin-resistant lung adenocarcinoma cells. Mol Med Rep 15(4):1693–1701.  https://doi.org/10.3892/mmr.2017.6170 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li J, Shen J, Wang K, Hornicek F, Duan Z (2016) The roles of sox family genes in sarcoma. Curr Drug Targets 17(15):1761–1772CrossRefPubMedGoogle Scholar
  25. 25.
    Liu H, Chen Y, Zhou F, Jie L, Pu L, Ju J, Li F, Dai Z, Wang X, Zhou S (2014) Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells. Int J Clin Exp Pathol 7(8):4795–4805PubMedPubMedCentralGoogle Scholar
  26. 26.
    Bao Y, Chen B, Wu Q, Hu K, Xi X, Zhu W, Zhong X, Chen J (2017) Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clin Exp Med 17(1):51–58.  https://doi.org/10.1007/s10238-015-0398-6 CrossRefPubMedGoogle Scholar
  27. 27.
    Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C (2005) Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol 168(7):1065–1076.  https://doi.org/10.1083/jcb.200409182 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Zou Y, Huang Y, Yang J, Wu J, Luo C (2017) miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity. Mol Med Rep 15(4):1631–1637.  https://doi.org/10.3892/mmr.2017.6187 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ren C, Ren T, Yang K, Wang S, Bao X, Zhang F, Guo W (2016) Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway. J Exp Clin Cancer Res 35:44.  https://doi.org/10.1186/s13046-016-0321-3 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Martins-Neves SR, Corver WE, Paiva-Oliveira DI, van den Akker BE, Briaire-de-Bruijn IH, Bovee JV, Gomes CM, Cleton-Jansen AM (2016) Osteosarcoma stem cells have active Wnt/beta-catenin and Overexpress SOX2 and KLF4. J Cell Physiol 231(4):876–886.  https://doi.org/10.1002/jcp.25179 CrossRefPubMedGoogle Scholar
  31. 31.
    Li C, Shi X, Zhou G, Liu X, Wu S, Zhao J (2013) The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma. Front Biosci 18:1384–1391CrossRefGoogle Scholar
  32. 32.
    Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202–1209.  https://doi.org/10.1172/JCI28551 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  1. 1.Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.School of Biomedical Engineering & Med-X Research InstituteShanghai Jiao Tong UniversityShanghaiChina
  3. 3.Engineering Research Center of Digital Medicine and Clinical TranslationMinistry of Education of People’s Republic of ChinaShanghaiChina

Personalised recommendations